These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8395463)

  • 21. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
    Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
    Front Immunol; 2019; 10():886. PubMed ID: 31068950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human polyclonal and monoclonal IgG and IgM complement 3 nephritic factors: evidence for idiotypic commonality.
    Tsokos GC; Stitzel AE; Patel AD; Hiramatsu M; Balow JE; Spitzer RE
    Clin Immunol Immunopathol; 1989 Oct; 53(1):113-22. PubMed ID: 2475285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
    Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
    Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production.
    Spitzer RE; Stitzel AE; Tsokos G
    Clin Immunol Immunopathol; 1992 Sep; 64(3):177-83. PubMed ID: 1386563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-factor B autoantibody in dense deposit disease.
    Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
    Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mechanisms of action and clinical importance of C3-nephritic-factor (author's transl)].
    Lanzer G; Pogglitsch H; Tilz GP
    Acta Med Austriaca; 1981; 8(1):7-13. PubMed ID: 6908995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
    Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
    Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.
    Strife CF; Prada AL; Clardy CW; Jackson E; Forristal J
    J Pediatr; 1990 May; 116(5):S98-102. PubMed ID: 2329415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of nephritic factor as an immunoglobulin.
    Williams DG; Bartlett A; Duffus P
    Clin Exp Immunol; 1978 Sep; 33(3):425-9. PubMed ID: 104814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
    Tanuma Y; Ohi H; Hatano M
    Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.
    Levy Y; George J; Yona E; Shoenfeld Y
    Immunol Res; 1998 Aug; 18(1):55-60. PubMed ID: 9724849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway.
    Hiramatsu M; Tsokos GC
    Clin Immunol Immunopathol; 1988 Jan; 46(1):91-9. PubMed ID: 2826058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoglobulin variable region gene analysis to the autoantibody-secreting B cells from tumors in association with paraneoplastic autoimmune multiorgan syndrome.
    Wang J; Bu D; Zhu X
    Int J Dermatol; 2007 Nov; 46(11):1146-54. PubMed ID: 17988333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the origin and control of C3NeF.
    Spitzer RE; Stitzel AE
    In Vivo; 1988; 2(1):79-81. PubMed ID: 2979821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of VH and VL genes of a monospecific human anti-myosin antibody produced by a B cell from the primary repertoire.
    Laroche-Traineau J; Biard-Piechaczyk M; Jacobin MJ; Chagnaud JL; Pau B; Nurden A; Clofent-Sanchez G
    Hum Antibodies; 1999; 9(3):177-88. PubMed ID: 10690632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.
    Daha MR; van Es LA
    J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of variable heavy and light chain regions of five HIV type 1-specific human monoclonal antibodies.
    van der Donk EM; Schutten M; Osterhaus AD; van der Heijden RW
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1639-49. PubMed ID: 7888223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.
    Ohi H; Watanabe S; Fujita T; Seki M; Hatano M
    J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.